April 2023 PVRI Community Call with Bradley Wertheim

27 April 2023

In this Community Call, we discussed:

Maternal outcomes among pregnant women with congenital heart disease–associated pulmonary hypertension
Proline and glucose metabolic reprogramming supports vascular endothelial and medial biomass in pulmonary arterial hypertension

Bradley Wertheim, Community Call Guest

Jason Weatherald, Community Call Host

Katrina Barry, Community Call Host

Tatiana Kudryashova, Community Call Host

Other materials on this topic

11 November 2025

Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: Treatment Patterns and Risk Trajectories

Pulmonary arterial hypertension (PAH) significantly impacts mortality and quality of life. Access to specialized care may differ between urban and rural patients, potentially influencing outcomes. This study compared the clinical course and treatment patterns of PAH patients from urban and rural settings treated at a single comprehensive care center.

Pulmonary Circulation

27 August 2025

Analysis of Clinical Characteristics of 54 Dead Pregnant Patients With Pulmonary Hypertension

To analyse the clinical characteristics and potential pregnancy outcomes of deceased pregnant women with pulmonary hypertension, we conducted a retrospective analysis of clinical data from 54 cases of pregnant women with pulmonary hypertension at The Third Affiliated Hospital of Guangzhou Medical University from May 2009 to February 2022.

Pulmonary Circulation

16 June 2025

How to include underrepresented patients into cardiovascular clinical trials

Presented at PVRI's Drug Discovery & Development Symposium 2025, by Cati Brown-Johnson, Stanford University School of Medicine

Members Only

16 June 2025

Addressing sex differences in treatment decisions and drug development

Presented at PVRI's Drug Discovery & Development Symposium 2025, by Deimante Hoppenot, Lithuanian University of Health Sciences